

	(ENGLISH OFFICE TRANSLATION)
<b>INNKALLING TIL ORDINÆR GENERALFORSAMLING</b>  <b>LYTIX BIOPHARMA AS</b> (organisasjonsnummer 985 889 635)	<b>NOTICE OF ANNUAL GENERAL MEETING</b>  <b>LYTIX BIOPHARMA AS</b> (company registration number 985 889 635)
Den 18. april 2023 kl. 13.00 avholdes det ordinær generalforsamling i Lytix Biopharma AS (" <b>Selskapet</b> "), i Sandakerveien 130, 0484 Oslo, Norge.	18 April 2023 at 13:00 Hours (CEST), an ordinary general meeting in Lytix Biopharma AS (the " <b>Company</b> ") will take place, at Sandakerveien 130, 0484 Oslo, Norway.
Generalforsamlingen vil bli åpnet av styrets leder, Gert Wilhelm Munthe, som vil opprette fortegnelse over møtende aksjeeiere og fullmakter.	The general meeting will be opened by the chairperson of the board of directors, Gert Wilhelm Munthe. The chairperson will register the attendance of shareholders present and proxies.
Følgende saker er på agendaen:	The following matters are on the agenda:
<b>1 VALG AV MØTELEDER</b>	<b>1 ELECTION OF A PERSON TO CHAIR THE MEETING</b>
<b>2 VALG AV ÉN PERSON TIL Å MEDUNDERTEGNE PROTOKOLLEN SAMMEN MED MØTELEDEREN</b>	<b>2 ELECTION OF A PERSON TO CO-SIGN THE MINUTES TOGETHER WITH THE CHAIR OF THE MEETING</b>
<b>3 GODKJENNELSE AV INNKALLING OG DAGSORDEN</b>	<b>3 APPROVAL OF NOTICE AND AGENDA</b>
Styret foreslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Innkallingen og dagsorden godkjennes."</i>	<i>"The notice and the agenda are approved."</i>
<b>4 GODKJENNELSE AV ÅRSREGNSKAPET OG ÅRSBERETNINGEN FOR REGNSKAPSÅRET 2022</b>	<b>4 APPROVAL OF THE ANNUAL ACCOUNTS AND THE ANNUAL REPORT FOR THE FINANCIAL YEAR 2022</b>
Styrets forslag til årsregnskap og årsberetning for regnskapsåret 2022, samt revisjonsberetningen, er vedlagt som <u>Vedlegg 1</u> til innkallingen.	The board of director's proposal for the annual accounts and the annual report for the financial year 2022, including the auditor's report, are attached to this notice as Appendix 1.
Styret foreslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Årsregnskapet og årsberetningen for regnskapsåret 2022 godkjennes".</i>	<i>"The annual accounts and the annual report for the financial year 2022 is approved".</i>
Videre foreslår styret at generalforsamlingen treffer følgende vedtak om utdeling av utbytte:	Further, the board of directors proposes that the general meeting passes the following resolution with respect to distribution of dividend:
<i>"Det utdeles ikke utbytte for regnskapsåret 2022."</i>	<i>"Dividends will not be distributed for the financial year 2022."</i>
<b>5 GODKJENNELSE AV REVISORS GODTGJØRELSE</b>	<b>5 APPROVAL OF THE AUDITOR'S REMUNERATION</b>
Styret forslår at generalforsamlingen treffer følgende vedtak:	The board of directors proposes that the general meeting passes the following resolution:
<i>"Godtgjørelse til revisor for revisjon og revisjonsrelaterte tjenester for regnskapsåret 2022 godkjennes etter regning."</i>	<i>"Remuneration to the auditor for audit and audit related costs for the financial year 2022 based on invoice is approved."</i>
<b>6 STYREFULLMAKT - KAPITALFORHØYELSE</b>	<b>6 BOARD AUTHORIZATION – SHARE CAPITAL INCREASE</b>
<b>6.1 Styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram</b>	<b>6.1 Board authorization to increase the share capital in connection to the Company's incentive program</b>
<b>Bakgrunn</b>	<b>Background</b>
Styret har i henhold til generalforsamlingens vedtak 21. april 2022 en fullmakt til å forhøye aksjekapitalen med inntil NOK 506.642,00	Pursuant to the resolution of the Annual General Meeting on 21 April 2022, the Board has an authorization to increase the share capital by up to NOK 506,642.00 related to the Company's option program for

<p>knyttet til Selskapets opsjonsprogram for styrets leder, styremedlemmer, ansatte og andre nøkkelpersoner.</p> <p>Denne fullmakten er gyldig frem til ordinær generalforsamling i 2024, dog ikke lenger enn til 21. april 2024.</p>	<p>the chairperson of the Board, board members, employees and other key personnel.</p> <p>This authorization is valid until the annual general meeting in 2024, but no longer than until 21 April 2024.</p>
<p><b>6.1.1 Ny styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram</b></p>	<p><b>6.1.1 New board authorization to increase the share capital in connection to the Company's option programs</b></p>
<p>Styret foreslår at generalforsamlingen fatter følgende vedtak om ny styrefullmakt knyttet til Selskapets opsjonsprogram som skal erstatte fullmakten som utløper på tidspunkt for ordinær generalforsamling 2024:</p>	<p>The Board of Directors proposes that the general meeting passes the following resolution on a new board authorization related to the Company's option program which will replace the authorization that expires at the time of the ordinary general meeting in 2024:</p>
<p><i>(i) I henhold til aksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital med inntil NOK 519.917,10 knyttet til Selskapets opsjonsprogram til styreformann, styremedlemmer, ansatte og andre nøkkelpersoner.</i></p> <p><i>(ii) Fullmakten gjelder frem til ordinær generalforsamling i 2025 er avholdt, dog ikke lenger enn til 18. april 2025.</i></p> <p><i>(iii) Aksjeeiernes fortrinnsrett til nye aksjer etter allmenn-aksjeloven § 10-4 skal kunne fravikes.</i></p> <p><i>(iv) Fullmakten omfatter også kapitalforhøyelse mot innskudd i andre eiendeler enn penger, herunder kapitalforhøyelse ved motregning.</i></p>	<p><i>(i) Pursuant to section 10-14 of the Norwegian Companies Act, the board is authorized to increase the Company's share capital by up to NOK 519,917.10 in connection with the Company's option program for the chairperson, board members, employees and other key persons.</i></p> <p><i>(ii) The authorization is valid until the annual general meeting in 2025 has been held, but no longer than until 18 April 2025.</i></p> <p><i>(iii) The shareholders' pre-emptive right to new shares pursuant to the Public Limited Liability Companies Act § 10-4 shall be waived.</i></p> <p><i>(iv) The authorization also includes a capital increase against deposits in assets other than cash, including a capital increase by set-off.</i></p>
<p><b>6.2 Styrefullmakt til generell kapitalforhøyelse</b></p>	<p><b>6.2 Board authorization to increase the share capital</b></p>
<p><b>Bakgrunn</b></p>	<p><b>Background</b></p>
<p>Styret ble på generalforsamling den 21. april 2022 tildelt en fullmakt til generelt å forhøye aksjekapitalen, i en eller flere omganger, med inntil NOK 400.683,19. Denne fullmakten gjelder fra generalforsamlingens beslutning og frem til ordinær generalforsamling i 2024, dog senest til 21. april 2024.</p> <p>For at Selskapet skal kunne ha mulighet til å gjennomføre fremtidige kapitalforhøyelser for å utstede nye aksjer på en rask og smidig måte, foreslås det at styrets fullmakt til å forhøye aksjekapitalen med inntil NOK 400,683,10 (tilsvarende ca. 10% av selskapets aksjekapital), med utstedelse av inntil 4,006,831.00 nye aksjer forlenges frem til 2025.</p>	<p>At the general meeting on 21 April 2022, the board was authorized to generally increase the share capital, in one or more rounds, by up to NOK 400,683.19. This authorization is valid from the decision of the general meeting until the annual general meeting in 2024, however no later than 21 April 2024.</p> <p>In order for the Company to be able to carry out future capital increases in order to issue new shares in a quick and flexible manner, it is proposed that the Board is authorized to increase the share capital by up to NOK 400,683.10 (corresponding to approximately 10% of the Company's share capital), with the issue of up to 4,006,831.00 new shares is extended until 2025.</p>
<p><b>6.2.1 Ny styrefullmakt til generell kapitalforhøyelse</b></p>	<p><b>6.2.1 New board authorization for general capital increase</b></p>
<p>Styret foreslår at generalforsamlingen fatter følgende vedtak om ny styrefullmakt:</p>	<p>The board proposes that the general meeting adopts the following resolution on a new board authorization:</p>
<p><i>(i) I henhold til aksjeloven § 10-14 gis styret fullmakt til å forhøye Selskapets aksjekapital, i en eller flere omganger, med inntil NOK 400.683,19.</i></p> <p><i>(ii) Fullmakten gjelder frem til ordinær generalforsamling i 2025 er avholdt, dog ikke lenger enn til 18. april 2025.</i></p> <p><i>(iii) Aksjonærenes fortrinnsrett til de nye aksjene kan fravikes, jf. aksjeloven § 10-5, jf. § 10-4.</i></p> <p><i>(iv) Fullmakten omfatter ikke kapitalforhøyelse ved fusjon etter aksjeloven § 13-5</i></p> <p><i>(v) Fullmakten omfatter ikke kapitalforhøyelse mot innskudd i andre eiendeler enn penger.</i></p>	<p><i>(i) Pursuant to section 10-14 of the Norwegian Companies Act, the board is authorized to increase the Company's share capital, in one or more rounds, by up to NOK 400,683.19.</i></p> <p><i>(ii) The authorization is valid until the annual general meeting in 2025 has been held, but no longer than until 18 April 2025.</i></p> <p><i>(iii) The shareholders' preferential right to the new shares may be deviated from, cf. Section 10-5, cf. Section 10-4 of the Companies Act.</i></p> <p><i>(iv) The authorisation does not include an increase in share capital through merger in accordance with Section 13-5 of the Companies Act.</i></p>

	(v) <i>The authorisation does not include an increase in share capital by contribution in kind.</i>
<b>7 VALG AV STYRE</b>	<b>7 ELECTION OF BOARD OF DIRECTORS</b>
<p>Det sittende styret ble på OGF 2021 valgt for en to-års periode frem til Selskapets ordinære generalforsamling i 2023.</p> <p>Som kommunisert under CEOs orientering i februar 2023 har selskapet kommet til et nytt kritisk stadium i utviklingen. N&amp;CC har evaluert dagens styresammensetning og konkludert med at det er behov for sterkere og tettere vitenskapelig støtte og sparring med administrerende direktør rundt selskapets kjerneteknologi.</p> <p>Da Gert Wilhelm Munthe trådte inn som leder av Lytix' styre, gjorde han det klart at hans oppgave ville være å bidra til å få selskapet på stø kurs og at han ville trekke seg når oppdraget hans var fullført. Vi takker Gert for hans solide engasjement, både som aktiv aksjonær og styredirektør. Selskapet tar nå nye grep, og en meget kompetent person har takket ja til å bli foreslått som kandidat til stillingen som ny styreleder i Lytix Biopharma AS.</p> <p>Tidligere i år informerte styrelederen N&amp;CC om at alle faste styremedlemmer hadde uttrykt både stor interesse og sterk motivasjon for å ta en ny periode. Så en ny styreleder kan dermed støtte seg til et styre som tilbyr både mangfold og kontinuitet i tillegg til hver av styremedlemmenes individuelle kompetanse.</p> <p>Den nye kandidaten er Marie Ann Roskrow. Hun er en erfaren toppleder med internasjonal erfaring innen legemiddelindustrien og tilsvarende finanssektor. Hun har en PhD i immunologi og innehar styreleder-posisjoner i internasjonale bioteknologi-selskaper, inkludert et norsk selskap. Hennes CV er vedlagt som vedlegg 3.</p> <p>I tråd med valgkomitéens innstilling (vedlegg 2) foreslår styret at Marie Ann Roskrow velges som ny styreleder for perioden frem til Selskapets ordinære generalforsamling i 2025.</p>	<p>The current board was elected at OGA 2021 up to and including the Company's ordinary general meeting in 2023.</p> <p>As communicated in the February 2023 CEO brief, the company has come to a new critical stage in its development. The N&amp;CC has evaluated the current Board Composition and has concluded that there is a need for stronger and closer scientific support and sparring for the CEO on the company's core technology.</p> <p>When Gert Wilhelm Munthe stepped in as Leader of Lytix' Board of Directors he made it clear that he was there to help bringing the company to a stable state, and that he would step down when his mission was completed. We thank Gert for his passion and energy as an active shareholder and director of the board. The company is now taking new steps, and a candidate very well equipped to take over has accepted to be presented as a candidate for the position as new Leader of the Board at Lytix Biopharma AS.</p> <p>Earlier this year the Chairperson informed the N&amp;CC, that all regular board members had expressed both high interest and strong motivation to take another term, so a new Chairperson can rely on a Board offering both diversity and continuity aside from the individual competencies present.</p> <p>The new candidate is Marie Ann Roskrow. She is an experienced senior executive with international experience in health care and financial sector. She has a PhD in Immunology and serves currently as Non-Executive Director in international biotech organizations – Norway included. Her CV is attached as Appendix 3.</p> <p>In line with the nomination committee's recommendation (appendix 2), the board proposes that Marie Ann Roskrow is to be elected as new chairperson for the period up to the Company's ordinary general meeting in 2025.</p>
Videre foreslås det at Gert Wilhelm Munthe trer ut av styret.	Furthermore, it is proposed that Gert Wilhelm Munthe resign from the board.
Dersom forslaget blir vedtatt av generalforsamlingen, vil det nye styret bestå av følgende personer:	If the proposal is approved by the general meeting, the new board will consist of the following people:
<ul style="list-style-type: none"> <li>• Marie Ann Roskrow (styreleder);</li> <li>• Brynjar Forbergskog (styremedlem);</li> <li>• Marie-Louise Fjällskog (styremedlem);</li> <li>• Kjetil Hestdal (styremedlem);</li> <li>• Evelina Vågesjö (styremedlem); og</li> <li>• Jayson Rieger (styremedlem).</li> </ul>	<ul style="list-style-type: none"> <li>• Marie Ann Roskrow (chairperson);</li> <li>• Brynjar Forbergskog;</li> <li>• Marie-Louise Fjällskog;</li> <li>• Kjetil Hestdal;</li> <li>• Evelina Vågesjö; and</li> <li>• Jayson Rieger.</li> </ul>
<b>8 VALG AV VALGKOMITÉ</b>	<b>8 ELECTION OF NOMINATION COMMITTEE</b>
Den sittende valgkomitéen ble på OGF i 2022 valgt frem til og med selskapets ordinære generalforsamling i 2023.	At Ordinary General Assembly 2021, the current nomination committee was elected until the Company's annual general meeting in 2023.
Valgkomitéen har avgitt sin innstilling om at nåværende medlemmer av valgkomitéen fortsetter sine verv frem til og med selskapets ordinære generalforsamling 2024 – ref. vedlegg 2.	The nomination committee has submitted its recommendation that the current members of the nomination committee continue their duties, ref Appendix 2, up to and including the Company's annual general meeting in 2024.

Styret foreslår at følgende personer velges til valgkomitéen for perioden frem til Selskapets neste ordinære generalforsamling:	The board proposes that the general meeting adopts the following resolution about the nomination committee:
<ul style="list-style-type: none"> <li>○ Per Erik Sørensen (leder)</li> <li>○ Lise von Tangen Jordan</li> <li>○ Steinar Thoresen</li> </ul>	<ul style="list-style-type: none"> <li>○ Per Erik Sørensen (chairperson)</li> <li>○ Lise von Tangen Jordan</li> <li>○ Steinar Thoresen</li> </ul>
<b>9 HONORAR TIL STYRETS MEDLEMMER</b>	<b>9 REMUNERATION TO THE MEMBERS OF THE BOARD OF DIRECTORS</b>
På OGF 2022 ble det vedtatt at styrets leder skulle motta NOK 360.000 og styremedlemmene NOK 240.000 for perioden fra generalforsamlingen 2021 frem til generalforsamlingen 2022. Videre foreslo valgkomitéen å holde godtgjørelsesnivået uendret for perioden frem til generalforsamlingen 2023.	At the ordinary general meeting 2022, it was decided that the chairperson of the board should receive NOK 360,000 and the board members NOK 240,000 for the period from the general meeting 2021 until the general meeting 2022. Furthermore, the nomination committee proposed to keep the remuneration level unchanged for the period until the general meeting 2023.
For perioden fra generalforsamlingen 2023 frem til generalforsamlingen 2024 foreslår valgkomitéen en godtgjørelse bestående av både kontanter og aksjeopsjoner, slik det er vanlig i det internasjonale kapitalmarkedet.  Valgkomitéen foreslår godtgjørelse i penger på NOK 360.000 til styrets leder og NOK 240.000 til styremedlemmene for perioden fra ordinær generalforsamling 2023 til ordinær generalforsamling 2024.	For the period from the annual general meeting 2023 until the annual general meeting 2024, the committee proposes a remuneration consisting both of cash and share options, as common in the international market.  The nomination committee propose an annual cash compensation of NOK 360,000 to the chairperson and 240,000 to the board members for the period from the annual general meeting 2023 until the annual general meeting in 2024.
Videre foreslår valgkomiteen at styrets leder tildeles 60.000 aksjeopsjoner og styremedlemmene 60.000 aksjeopsjoner hver.	Furthermore, the nomination committee proposes that the chairperson will be awarded 60,000 share options and the board members 60,000 share options each.
Styret foreslår at både honorar for perioden 2022-2023 og 2023-2024 vedtas av generalforsamlingen, slik at generalforsamlingene fremover bare skal bestemme honorar for påfølgende periode.  I samsvar med valgkomitéens innstilling foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til styrets medlemmer:	The board proposes that fees for both the period 2022-2023 and 2023-2024 is adopted by the general meeting, so that going forward, the annual general meetings only resolve fees for the following period.  In accordance with the nomination committee's proposal, the board of directors propose that the general meeting resolves the following regarding remuneration to the members of the board of directors:
«Generalforsamlingen godkjenner følgende honorar til styrets medlemmer for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:	"The general meeting approves the following remuneration to the members of the board of directors for the period from the annual general meeting in 2022 to the annual general meeting in 2023:
Styrets leder, Gert Wilhelm Munthe, skal motta NOK 360.000.	The chairperson, Gert Wilhelm Munthe, shall receive NOK 360,000.
<ul style="list-style-type: none"> <li>• Styremedlemmene skal motta NOK 240.000 hver <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö»</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• The Board members shall receive NOK 240,000 each <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö"</li> </ul> </li> </ul>
«Generalforsamlingen godkjenner følgende honorar til styrets medlemmer for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:	"The general meeting approves the following remuneration to the members of the board of directors for the period from the annual general meeting in 2023 to the annual general meeting in 2024:
Styrets leder, Marie Ann Roskrow, skal motta NOK 360.000	The chairperson, Marie Ann Roskrow, shall receive NOK 360,000.
<ul style="list-style-type: none"> <li>• Styremedlemmene skal motta NOK 240.000 hver <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• The Board members shall receive NOK 240,000 each <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> </ul> </li> </ul>

<ul style="list-style-type: none"> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö»</li> </ul>	<ul style="list-style-type: none"> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö"</li> </ul>
«Generalforsamlingen godkjenner følgende aksjeopsjoner til styrets medlemmer for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:	"The general meeting approves the following share options to the members of the board of directors for the period from the annual general meeting in 2023 to the annual general meeting in 2024:
Styrets leder, Marie Ann Roskrow, skal motta 60.000 aksjeopsjoner.	The chairperson, Marie Ann Roskrow, shall receive 60,000 share options.
<ul style="list-style-type: none"> <li>• Styremedlemmene skal motta 60.000 aksjeopsjoner hver <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö</li> </ul> </li> </ul> <p>Opsjonene vil opptjenes gradvis i henhold til en spesifikk opptjeningsplan: 1/4 av opsjonene vil opptjenes 12 måneder etter tildelingsdatoen, mens de resterende 3/4 av opsjonene vil opptjenes med 1/36 på den siste dagen av de 36 følgende måneder.</p> <p>Utøvelseskursen vil bli satt lik sluttkursen på datoen for innkalling til ordinær generalforsamling, 11. april 2023. Aksjeopsjonene vil utløpe 11. april 2028. Andre vilkår i henhold til selskapets opsjonsprogram.»</p>	<ul style="list-style-type: none"> <li>• The Board members shall receive 60,000 share options each <ul style="list-style-type: none"> <li>○ Marie-Louise Fjällskog</li> <li>○ Brynjar Forbergskog</li> <li>○ Kjetil Hestdal</li> <li>○ Jayson Rieger</li> <li>○ Evelina Vågesjö</li> </ul> </li> </ul> <p>The options will vest gradually pursuant to a specific vesting schedule: 1/4 of the options will vest on the day 12 months after the date of grant, while the remaining 3/4 of the options will vest with 1/36 on the last day of the 36 following months.</p> <p>The exercise price will be set equal to the closing price on the date of the Notice to Annual General Meeting, 11 April 2023. The share options will expire on 11 April 2028. Other conditions according to the company's option program."</p>
<b>10 HONORAR TIL MEDLEMMER AV VALGKOMITEEN</b>	<b>10 REMUNERATION TO THE MEMBERS OF THE NOMINATION COMMITTEE</b>
På OGF 2022 ble det vedtatt at valgkomitéens leder skulle motta NOK 60.000 og komitéens medlemmer NOK 50.000 hver for perioden fra generalforsamlingen 2021 frem til generalforsamlingen 2022. Videre foreslo valgkomitéen at godtgjørelsesnivået skulle holdes uendret for perioden frem til generalforsamlingen 2023.	At the annual general meeting 2022, it was decided that the chairperson of the nomination committee should receive NOK 60,000 and the committee members NOK 50,000 each for the period from the general meeting 2021 until the general meeting 2022.
For perioden fra generalforsamlingen 2023 frem til generalforsamlingen 2024 foreslår valgkomiteen følgende godtgjørelse: valgkomitéens leder skal motta NOK 60.000 og valgkomitéens medlemmer skal motta NOK 50.000.	For the period from the annual general meeting 2023 until the annual general meeting 2024, the nomination committee proposes the following remuneration: the chairperson shall receive NOK 60,000 and the members of the nomination committee shall receive NOK 50,000.
Styret foreslår at honorar for begge periodene 2022-2023 og 2023-2024 vedtas av generalforsamlingen slik at generalforsamlingene fremover bare skal bestemme honorar for påfølgende periode.	The board proposes that fees for both periods 2022-2023 and 2023-2024 shall be adopted by the general meeting so that the general meetings in the future only decide fees for the following period.
I samsvar med valgkomiteens innstilling foreslår styret at generalforsamlingen treffer følgende vedtak om honorar til valgkomitéens medlemmer.	In accordance with the nomination committee's proposal, the board proposes that the general meeting make the following resolution on the remuneration of the nomination committee's members:
«Generalforsamlingen godkjenner følgende honorar til valgkomitéens medlemmer for perioden fra ordinær generalforsamling i 2022 til ordinær generalforsamling i 2023:	"The general meeting approves the following remuneration to the members of the nomination committee for the period from the annual general meeting in 2022 to the annual general meeting in 2023:
Valgkomitéens leder, Per Erik Sørensen, skal motta NOK 60.000.	The chairperson of the nomination committee Per Erik Sørensen shall receive NOK 60,000.
<ul style="list-style-type: none"> <li>• Medlemmene i valgkomitéen skal motta NOK 50.000 hver <ul style="list-style-type: none"> <li>○ Lise von Tangen Jordan</li> <li>○ Steinar Thoresen»</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• The members of the nomination committee shall receive NOK 50,000 each <ul style="list-style-type: none"> <li>○ Lise von Tangen Jordan</li> </ul> </li> </ul>

	<ul style="list-style-type: none"> <li>o Steinar Thoresen"</li> </ul>
«Generalforsamlingen godkjenner følgende honorar til valgkomiteens medlemmer for perioden fra ordinær generalforsamling i 2023 til ordinær generalforsamling i 2024:	"The general meeting approves the following remuneration to the members of the board of directors for the period from the annual general meeting in 2023 to the annual general meeting in 2024:
Valgkomiteens leder, Per Erik Sørensen, skal motta NOK 60.000	The chairperson of the nomination committee Per Erik Sørensen shall receive NOK 60,000.
<ul style="list-style-type: none"> <li>• Medlemmene i valgkomiteen skal motta NOK 50.000 hver <ul style="list-style-type: none"> <li>o Lise von Tangen Jordan</li> <li>o Steinar Thoresen»</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• The members of the nomination committee shall receive NOK 50,000 each <ul style="list-style-type: none"> <li>o Lise von Tangen Jordan</li> <li>o Steinar Thoresen"</li> </ul> </li> </ul>
<b>11 VEDTEKTER</b>	<b>11 ARTICLES OF ASSOCIATION</b>
<p>Styret har hatt en gjennomgang av Lytix' vedtekter. Basert på denne gjennomgangen foreslår styret følgende endringer:</p> <ul style="list-style-type: none"> <li>• Medlemmer av valgkomiteen velges av generalforsamlingen for 1 år av gangen. Valgkomiteens skal ha en leder som velges av generalforsamlingen.</li> <li>• Fjerne setning om at generalforsamling kan avholdes i Oslo. Denne setningen er ikke relevant etter at selskapet avviklet kontoret i Tromsø og nå kun har Oslo-adresse.</li> </ul> <p>Styret foreslår at forslag til nye vedtekter inntatt som Vedlegg 4 godkjennes av generalforsamlingen.</p>	<p>The board has had a review of Lytix' articles of association. Based on this review, the board proposes the following changes:</p> <ul style="list-style-type: none"> <li>• Members of the nomination committee are elected by the general meeting for 1 year at a time. The nomination committee shall have a chairperson who shall be elected by the general meeting.</li> </ul> <p>Remove the sentence that the general meeting can be held in Oslo. This sentence is not relevant after the company closed the office in Tromsø and now only has an Oslo address.</p> <p>The board proposes that the new articles of association attached as Appendix 4 are approved by the general meeting.</p>
* * *	* * *
<p>Dersom du/dere ønsker å delta på generalforsamlingen ber vi om at vedlagte møteseddel sendes til <a href="mailto:post@lytixbiopharma.com">post@lytixbiopharma.com</a> innen 17 april 2023, kl.16.00.</p> <p>Aksjeeiere som ikke ønsker å delta på generalforsamlingen henstilles om å fylle ut vedlagte fullmaktsskjema og sende det til <a href="mailto:post@lytixbiopharma.com">post@lytixbiopharma.com</a> innen 17. april 2023, kl. 16.00.</p>	<p>Shareholders who want to attend the general meeting are requested to complete the attendance slip and send it by e-mail to <a href="mailto:post@lytixbiopharma.com">post@lytixbiopharma.com</a> latest April 17, 2023 at 16.00 CET.</p> <p>Shareholders who do not wish to attend the general meeting are recommended to complete the enclosed power of attorney and return to <a href="mailto:post@lytixbiopharma.com">post@lytixbiopharma.com</a>, within April 17, 2023, at 16.00 CET.</p>
* * *	* * *
11 April 2023	
<b>På vegne av styret / On behalf of the Board of Directors of Lytix Biopharma AS</b>	
Gert Wilhelm Munthe Styrets leder / Chairperson of the board	
<p><b>Vedlegg:</b></p> <ol style="list-style-type: none"> <li>1 Årsregnskap, årsberetning og revisjonsberetning for 2022</li> <li>2 Innstilling fra nominasjonskomiteen</li> <li>3 Marie Ann Roskrow CV</li> <li>4 Vedtekter</li> <li>5 Møte- og fullmakts-seddel</li> </ol>	<p><b>Appendices:</b></p> <ol style="list-style-type: none"> <li>1 Annual accounts, annual report and auditors report for 2022</li> <li>2 Motion from the Nomination Committee</li> <li>3 Marie Ann Roskrow CV</li> <li>4 Articles of association</li> <li>5 Attendance slip and Power of attorney</li> </ol>

## Vedlegg 2 / Appendix 2

### 2023 Nomination & Compensation Committee – Lytix Biopharma AS

#### 2023 NOMINATION & COMPENSATION COMMITTEE – LYTIX BIOPHARMA AS

The 'Committee mandate is restricted to:

- A. Nominate board candidates and candidates for the Nomination & Compensation Committee for the shareholders on the General Assembly to vote on.
- B. Give advice on potential demands for employee board representation to the Assembly.
- C. Oversee and propose board and committee remuneration levels.

In connection with the upcoming General Meeting of Lytix Biopharma AS ("Lytix" or the "Company"), the Nomination and Compensation Committee (the "N&CC ") has been asked to review the board composition of the Company.

#### 1. BOARD COMPOSITION

As communicated in the February 2023 CEO briefing the company has come to a new critical stage in its development. The N&CC has evaluated the current Board Composition and has concluded that there is need for stronger and closer scientific support and sparring for the CEO on the company's core technology.

When Gert Wilhelm Munthe stepped in as Leader of Lytix Board of Directors he made it clear, that he was there to help bringing the company to a stable state, and that he would step down when his mission was completed. We thank Gert for his obvious passion and energy as an activ shareholder and director. The company is now taking new steps, and fortunately a candidate very well equipped to take over has accepted to be presented as a candidate for the position as new Leader of the Board at Lytix Biopharma AS.

Earlier this year the Chairperson informed the N&CC, that al regular board members had expressed both high interest and strong motivation to take another term, so a new Chairperson can rely on a Board offering both diversity and continuity aside from the individual competencies present.

The new candidate is **Marie Ann Roskrow**. She is an experienced senior executive with international experience in health care and financial sector. She has a PhD in Immunology and serves currently as Non-Executive Director in international biotech organizations – Norway included. For further information an extensive CV can be found attached to this nomination letter.

**The Board of Directors** will accordingly continue with the following composition:

*Marie Ann Roskrow (Chairperson)*  
*Marie-Louise Fjällskog*  
*Kjetil Hestdal*  
*Evelina Vågesjö*  
*Jayson Rieger*  
*Brynjar Forbergskog*

**The N&CC** proposes that the members are re-elected for a period to the AGM 2024. Then, for the next period, the N&CC will consist of the following members:

*Lise Von Tangen-Jordan*  
*Steinar Thoresen*  
*Per Erik Sørensen (Chairperson)*

## 2. EMPLOYEE BOARD REPRESENTATION

The N&CC has not identified immediate demands for employee board representation.

## 3. OVERSEE AND PROPOSE BOARD AND COMMITTEE REMUNERATION LEVELS.

### Remuneration of the Board of Directors:

N&CC also suggests that the remuneration levels are made available for board members for the last year as well as the coming year. This will make our processes and politics aligned with market practice in Norway.

Board remuneration for 2022/2023 is proposed to continue at the same level as the previous period:

Chairperson	360.000 NOK
Regular Members	240.000 NOK

For the period 2023/2024 the N&CC proposes a remuneration consisting both of cash and share options as is common in the international market. This is in line with the internationalization of the Company and its board composition.,

Annual cash compensation for 2023/2024:

Chairperson	360.000 NOK
Regular Members	240.000 NOK

Equity compensation for 2023/2024:

The N&CC also proposes that the chairperson and each board member is granted 60,000 share options, in total 360,000 share options on such terms as set out in the notice of the Annual General Meeting.

### Remuneration of the Nomination and Compensation Committee:

The N&CC proposes the following compensation to its members for the both the 2022/2023 period and the 2023/2024 period:

N&CC Chairperson	60.000 NOK
N&CC Members	50.000 NOK

Remuneration to board members can, as of the next pay-out, be fully or partially converted to company shares according to price tags regulated in the power of attorney given to the board by the general assembly.

Copenhagen, March 31<sup>st</sup> 2023

Steinar Thoresen

Lise von Tangen-Jordan

Per Erik Sørensen



## Vedlegg 3 / Appendix 3

### Marie Ann Roskrow CV

#### DR MARIE ANN ROSKROW

Field View, School Lane, Broadholme, Lincoln. LN1 2LZ

Ph. +44 (0) 7496959743 [mroskrow@gmail.com](mailto:mroskrow@gmail.com)

#### CAREER OVERVIEW

A motivated and outcome-driven senior executive with international experience in the healthcare and financial sectors.

#### CORE CAPABILITIES

- Strong strategic management skills and commercial acumen. Extensive “C-Suite” and Board experience.
- An “inclusive” leader with skills in teamwork, decision making, communication and presentation.
- Negotiating cross-border and local business transactions, using commercial, financial, scientific and medical knowledge.
- Fund-raising (private and public companies), IPO listings.
- Delivery on challenging business goals using open and transparent communications with all stakeholders, including Boards, shareholders and statutory bodies.
- Identifying, building and mentoring of capable, competent and motivated management teams.
- Scientific and medical expertise (including design and execution of clinical trials) in haematology, oncology and infectious diseases.

#### PROFESSIONAL QUALIFICATIONS

- |   |      |
|---|------|
| • Ph.D (Immunology), University of London           | 1997 |
| • MBBS (Honours in Pathology), University of London | 1991 |
| • BSc Haematology (Honours), University of London   | 1989 |

#### BOARD DIRECTORSHIPS

- |   |            |
|---|------------|
| • Chairman, PBD Biotech (UK, Private Company)                   | Since 2023 |
| • Chairman, Arcticzymes Technologies (Norway, Public Company)   | Since 2018 |
| • Chairman, Kinomica (UK, Private Company)                      | 2019-2020  |
| • Chairman, MetaLinear (UK, Private Company)                    | 2019-2020  |
| • Managing Director, Patrys Ltd (Australia, Public Company)     | 2011-2014  |
| • Chairman, Roskrow & Partners Ltd (Australia, Private Company) | 2008-2011  |
| • Director, Grace’s Children’s Academy ( USA, Charity)          | 2005-2007  |

#### CAREER HISTORY

- |   |           |
|---|-----------|
| • CEO & CMO, Imevax, Munich Germany   | 2015-2018 |
| • CEO & Managing Director, Patrys Ltd, Australia & UK                         | 2011-2014 |
| • CMO, Patrys Ltd, Australia  | 2010-2011 |
| • Founding Partner, Roskrow & Partners Ltd, Australia                         | 2008-2010 |
| • Healthcare Investment Banking, Lazard Ltd, New York, San Francisco & Sydney | 2000-2008 |
| • Group Leader & Physician, GSF / Ludwig Maximilians University, Munich       | 1997-2000 |
| • Research Fellowship, St Jude Children’s Hospital, Memphis                   | 1994-1997 |
| • Various Medical Positions, London Teaching Hospitals, London                | 1991-1994 |

## WORK HISTORY

### IMEVAX GmbH, MUNICH GERMANY

Chief Executive Officer

2015-2018

This venture-capital backed early-stage company operates in Munich, Germany.

- Streamlined and focussed the company on developing a novel therapeutic vaccine for the treatment of patients with resistant *Helicobacter pylori* and a complementary rapid diagnostic test.
- Advised the Board of Directors on Company strategy and direction. Raised EURO 26M from grants and venture capital investors.
- Acted as Chief Medical Officer (in addition to CEO) advancing the lead product from discovery-phase through preclinical development and completion of Phase 1a/b clinical testing. Led protocol design and writing, interaction with the EMEA / Paul Ehrlich Institute and setting up of a multi-centre clinical trial.
- Responsible for all aspects of scientific research, coordinating operations and managing a team of 25 scientists and supporting staff.
- Presented the Company at international conferences.

### PATRY'S LTD, MELBOURNE, LONDON & WURZBURG

Chief Executive Officer & Managing Director

2011-2014

This publically-traded biotechnology company has operations in Melbourne, Australia and Wurzburg, Germany.

- Restructured and refocussed the company on developing novel antibody therapies for the treatment of patients with cancer. Advanced lead product from pre-clinical development and through a successful Phase 1b clinical trial. Progressed pipeline of monoclonal antibody first-in-class therapeutics.
- Advised the Board of Directors on Company strategy and direction.
- Built and managed a multi-operational team of 22. Managed operations in Australia and Germany.
- Successfully raised over \$23m of new capital in two years.
- Negotiated several research collaborations with leading Universities and biotechnology companies.
- Presented company at international conferences (scientific and investment / shareholder focussed).

### ROSKROW & PARTNERS LTD, SYDNEY

Founder / Managing Partner

2008-2011

Established and managed a cross-functional team of 18 employees focussed on providing advisory services for the life-sciences sector. Worked with several international biotechnology companies advising on deal structures, financing options, valuation and financial modelling, out-licensing of scientific programmes and sales of assets. Worked closely with senior management teams, boards of directors and investors.

### LAZARD, NEW YORK, SAN FRANCISCO & SYDNEY

Healthcare Investment Banker

2000-2008

- Responsible for pitching to prospective clients and negotiating / executing engagement letters.
- Executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures, asset divestitures, spin-offs and in / out-licensing of preclinical and preclinical programmes.

- Extensive cross-border deal experience. Developed a significant international network within the pharmaceutical / biotechnology sectors.
- Involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt.
- Conducted extensive scientific and medical due diligence. Responsible for clinical data analysis, statistical analysis and scientific team reports.
- Mentored and lead team of junior and mid-level investment bankers.

**GSF RESEARCH INSTITUTE (HELMHOLTZ ZENTRUM), MUNICH**

**Group Leader & Physician in the Transplant Unit**

**1997-2000**

- Secured major grant funding for the group by winning a Gerhard Hess Prize from the Deutsche Forschungsgemeinschaft (DFG).
- Recruited, trained and mentored a group of 15 scientists and technicians.
- Translated original laboratory-based research into early-phase clinical trials in patients with cancer. Focussed on novel dendritic cell vaccine development, T cell immunotherapies and vector development for gene therapies.
- Presented scientific work at major international conferences. Published >20 peer-reviewed articles.
- Taught immunology and haematology to medical students. Mentored several PhD students.

**ST JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS**

**Research Fellowship**

**1994-1997**

Researched novel T cell-based therapies for the treatment of children with Hodgkin disease; this work resulted in the initiation of a successful Phase I clinical trial and several publications in major journals. Resulted in obtaining a PhD in immunology.

**UNIVERSITY TEACHING HOSPITALS, LONDON**

**Physician specialising in haematology / immunology**

**1991-1994**

## Vedlegg 4 / Appendix 4

### Vedtekter / Articles of association

#### VEDTEKTER FOR LYTIX BIOPHARMA AS

(Vedtatt [●] april 2023)

**§ 1 Foretaksnavn**

Selskapets foretaksnavn er Lytix Biopharma AS.

**§ 2 Forretningskontor**

Selskapets forretningskontor er i Oslo kommune.

**§ 3 Virksomhet**

Selskapets virksomhet er:

Utvikling, markedsføring og salg av farmasøytiske og bioteknologiske produkter, samt dertil hørende virksomhet. Selskapet kan ha eierinteresser i foretak innen samme eller tilstøtende bransjer.

**§ 4 Selskapets aksjekapital**

Selskapets aksjekapital er NOK 4.006.831,9 fordelt på 40.068.319 aksjer hver pålydende NOK 0,1.

**§ 5 Aksjeeierregistrering**

Selskapets aksjer skal være registrert i et verdipapirregister (VPS).

**§ 6 Overdragelse av aksjer**

Selskapets aksjer er fritt omsettelige, uten krav til samtykke fra styret eller forkjøpsrett for de øvrige aksjeeiere.

**§ 7 Styre**

Selskapets styre skal ha tre til ni medlemmer etter generalforsamlingens nærmere beslutning. Styrets leder velges av generalforsamlingen.

**§ 8 Signatur**

Selskapets firma skal tegnes av to styremedlemmer i fellesskap.

**§ 9 Generalforsamlinger**

På den ordinære generalforsamlingen skal følgende saker behandles og avgjøres:

1. Godkjenning av årsregnskapet og årsberetningen, herunder utdeling av utbytte.
2. Andre saker som etter loven eller vedtektene hører under generalforsamlingen.

~~Selskapets generalforsamlinger kan avholdes i Oslo kommune.~~

**§ 10 Bruk av elektronisk kommunikasjon ved innkalling til generalforsamling**

Dokumenter som gjelder saker som skal behandles på generalforsamlingen behøver ikke sendes til aksjeeierne dersom dokumentene er tilgjengelige på selskapets nettsider. Dette gjelder også dokumenter som etter lov skal inntas i eller vedlegges innkallingen til generalforsamlingen. En aksjeeier kan likevel kreve å få tilsendt dokumenter som gjelder saker som skal behandles på generalforsamlingen.

**§ 11 Valgkomité**

Selskapet skal ha en valgkomité som velges av generalforsamlingen for ett år av gangen og det skal utarbeides en instruks for valgkomitéen. Valgkomiteens leder velges av generalforsamlingen.

**STATUTES OF LYTIX BIOPHARMA AS**  
(Adopted on April [●], 2023 / Translation to English)

**§ 1 Company name**

The company's name is Lytix Biopharma AS.

**§ 2 Office**

The company's registered office is in the municipality of Oslo, Norway.

**§ 3 Business**

The company's activities are:

Development, marketing and sales of pharmaceutical and biotechnology products, as well as associated business activities. The company may have ownership interests in entities within the same or related industries.

**§ 4 The company's share capital**

The company's share capital is NOK 4,006,831.9 divided into 40,068,319 shares each with a nominal value of NOK 0.1.

**§ 5 Shareholders Registration**

The company's shares shall be registered in a central securities depository (VPS).

**§ 6 Transfer of shares**

The company's shares are freely transferable, without requiring the consent of the board and without first refusal for the remaining shareholders.

**§ 7 Board of directors**

The company's board of directors shall consist of three to nine members as decided by the general meeting. The chairperson shall be elected by the general meeting.

**§ 8 Signature**

Two members of the board of directors jointly have the authority sign for and on behalf of the company.

**§ 9 Annual general meeting**

The annual general meeting shall address and decide upon the following matters:

1. Approval of the annual report and the annual accounts, including distribution of dividend.
2. Any other matters, which according to law or statutes shall be addressed at the general meeting.

~~The company's general meetings may be held in the municipalities of Oslo.~~

**§ 10 Electronic distribution of documents for the general meeting**

Documents relating to matters which shall be considered at the general meeting, including documents which according to law shall be included in or attached to the notice convening the general meeting, do not need to be sent to the shareholders if the documents have been made available on the company's webpage. A shareholder may nevertheless request that documents relating to matters to be considered at the general meeting are sent to the shareholder.

**§ 11 Nomination committee**

The Company shall have a nomination committee elected by the General Assembly for one-year terms and instructions for the nomination committee shall be prepared. The chairperson of the nomination committee shall be elected by the general meeting.

## Vedlegg 5 / Appendix 5

### PÅMELDING – ORDINÆR GENERALFORSAMLING 18. APRIL 2023 I LYTIX BIOPHARMA AS

Melding om at De vil delta i den ordinære generalforsamlingen gis ved å benytte denne møteseddel. Det bes om at signert skjema sendes til [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) senest den 17. april 2023, kl. 16:00. Dersom De etter påmelding skulle bli forhindret fra å møte, kan skriftlig og datert fullmakt leveres på den ordinære generalforsamlingen.

Undertegnede vil møte på den ordinære generalforsamlingen i Lytix Biopharma AS den 18. april og (sett kryss):

- Avgi stemme for mine/våre aksjer
- Avgi stemme for aksjer ifølge vedlagte fullmakt(er)

Navn på aksjonær / selskap (blokkbokstaver): \_\_\_\_\_

Antall egne aksjer: \_\_\_\_\_

Antall aksjer som eventuelt representeres etter fullmakt: \_\_\_\_\_

\_\_\_\_\_  
dato

\_\_\_\_\_  
sted

\_\_\_\_\_  
aksjonærens underskrift

---

### REGISTRATION – ANNUAL GENERAL MEETING APRIL 18, 2023 IN LYTIX BIOPHARMA AS

Notice of attendance at the Annual General Meeting is asked to be sent via this attendance slip. Kindly submit the signed notice by email to [post@lytixbiopharma.com](mailto:post@lytixbiopharma.com) no later than April 17, 2023, 16:00 CET. If you are unable to attend after you have registered, a written and dated proxy can be submitted at the annual general meeting.

The undersigned will attend the Annual general meeting of Lytix Biopharma AS April 18, 2022 and (tick-off):

- Vote for my/our shares
- Vote for shares pursuant to enclosed proxy(ies)

Shareholder's name / company name (capital letters): \_\_\_\_\_

Number of own shares: \_\_\_\_\_

Number of shares represented by proxy: \_\_\_\_\_

\_\_\_\_\_  
Date

\_\_\_\_\_  
Place

\_\_\_\_\_  
Shareholder's signature

**LYTIX BIOPHARMA AS**  
**FULLMAKTSSKJEMA TIL ORDINÆR GENERALFORSAMLING DEN 18. april 2022**

Aksjeeiere som ikke selv møter på den ordinære generalforsamlingen i Lytix Biopharma AS den 18. april 2023, bes om å fylle ut denne fullmakten og sende den **per e-post til post@lytixbiopharma.com**.

Fullmaktsskjema bes sendes slik at det er kommet frem til Selskapet **senest den 17. april 2023 kl. 16:00**.

Undertegnede gir herved (sett kryss):

<input type="checkbox"/>	Styrets leder, Gert Wilhelm Munthe, eller den han bemyndiger
<input type="checkbox"/>	Den som skal lede generalforsamlingen
<input type="checkbox"/>	_____
	Navn på fullmektig

fullmakt til å møte og representere meg/oss på den ordinære generalforsamlingen i Lytix Biopharma AS den 18. april 2023. Dersom det er sendt inn fullmakt uten avkryssing ovenfor, anses fullmakten gitt til styrets leder, Gert Wilhelm Munthe, eller den han bemyndiger.

Stemmegivningen skal skje i henhold til instruksjonene nedenfor. Merk at **dersom det ikke er kryssset av i rubrikkene nedenfor, vil dette anses som en instruks om å stemme "for" forslagene i innkallingen**, likevel slik at fullmektigen avgjør stemmegivningen i den grad det blir fremmet forslag i tillegg til, til erstatning for, eller som endring i forslagene i innkallingen.

	Sak	For	Mot	Avstår	Fullmektig avgjør
<b>1</b>	Valg av møteleder				
<b>2</b>	Valg av én person til å medundertegne protokollen sammen med møtelederen				
<b>3</b>	Godkjenning av innkalling og dagsorden				
<b>4</b>	Godkjenning av årsregnskapet og årsberetningen for regnskapsåret 2021				
<b>5</b>	Godkjenning av revisors godtgjørelse				
<b>6.1</b>	Styrefullmakt til kapitalforhøyelse knyttet til Selskapets opsjonsprogram				
<b>6.2</b>	Styrefullmakt til generell kapitalforhøyelse				
<b>7</b>	Valg av styre og valgkomité				
<b>8</b>	Valg av valgkomité				
<b>9</b>	Honorar til styrets medlemmer				
<b>10</b>	Honorar til medlemmer av valgkomitéen				
<b>11</b>	Vedtekter				

Aksjeeierens navn: \_\_\_\_\_  
(Vennligst benytt blokkbokstaver)

Antall aksjer: \_\_\_\_\_

\_\_\_\_\_ Dato                      \_\_\_\_\_ Sted                      \_\_\_\_\_ Aksjeeierens underskrift

Dersom aksjeeieren er et selskap, eller annen juridisk enhet, skal dokumentasjon i form av firmaattest, og eventuelt fullmakt, vedlegges fullmakten.

**LYTIX BIOPHARMA AS**  
**PROXY FORM TO THE ANNUAL GENERAL MEETING ON 18 APRIL 2023**

Shareholders who will not attend the annual general meeting on 18 April 2023 in person, are asked to complete this proxy form and return it **per e-mail to post@lytixbiopharma.com**.

The proxy form should be received by the Company **no later than 17 April 2023 at 16:00 hours (CEST)**.

The undersigned hereby grants (please tick):

<input type="checkbox"/>	The chairperson of the board, Gert Wilhelm Munthe, or the person he appoints,
<input type="checkbox"/>	Den som skal lede generalforsamlingen
<input type="checkbox"/>	_____
	Navn på fullmektig

power of attorney to attend and vote for my/our shares at the annual general meeting of Lytix Biopharma AS to be held on 18 April 2023. If the proxy form is submitted without ticking of the box above, the proxy will be deemed to have been given to the chairperson of the board of directors, Gert Wilhelm Munthe, or the person he appoints.

The votes shall be cast in accordance with the instructions below. Please note that **if the alternatives below are not ticked off, this will be deemed to be an instruction to vote "in favour" of the proposals in the notice**, provided, however, that the proxy holder determines the voting to the extent proposals are put forward in addition to, instead of, or as adjustments to the proposals in the notice.

	Item	In favour	Against	Abstain	At the proxy's discretion
1	Election of a person to chair the meeting				
2	Election of a person to co-sign the minutes together with the chair of the meeting				
3	Approval of the notice and the agenda				
4	Approval of the annual accounts and the annual report for the financial year 2021				
5	Approval of the auditor's remuneration				
6.1	Board authorization to increase the share capital in connection to the Company's incentive program				
6.2	Board authorization to increase the share capital				
7	Election of board of directors				
8	Election of nomination committee				
9	Remuneration to the members of the board of directors				
10	Remuneration to the members of the nomination committee				
11	Articles of association				

The shareholder's name: \_\_\_\_\_  
(Please use capital letters)

Number of shares: \_\_\_\_\_

\_\_\_\_\_ Date

\_\_\_\_\_ Place

\_\_\_\_\_ Shareholder's signature

If the shareholder is a legal entity, please attach documentation in the form of certificate of registration, or separate power of attorney, if applicable, to this power of attorney.